EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells

Luca, Antonella De; Casamassimi, Amelia; Selvam, M P; Losito, Simona; Ciardiello, Fortunato; Agrawal, Sudhir; Salomon, David; Normanno, Nicola

doi:10.1002/(sici)1097-0215(19990209)80:4<589::aid-ijc17>3.0.co;2-d

Cited by 43 publications

(24 citation statements)

References 14 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A protective role of the EGF-like growth factors against apoptosis has been demonstrated in several non-transformed and tumor cell types (52)(53)(54)(55)(56). Accordingly, anti-apoptotic activity of AR has been suggested by a study in human breast carcinoma cells (48). AR is overexpressed in a significant percentage of tumorigenic human lung epithelial cells (7).…”

Section: Ar and Igf1 Inhibit Serum Deprivation Apoptosis Of H358 And mentioning

confidence: 99%

Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines

Hurbin¹,

Dubrez²,

Coll

et al. 2002

Journal of Biological Chemistry

View full text Add to dashboard Cite

Several abnormalities in the insulin-like growth factor-1 (IGF1) and erbB receptors pathways stimulate the growth and survival of lung cancer cells, but their mechanisms of action and cooperation are poorly understood. In this report, we have identified a new mechanism of apoptosis inhibition by amphiregulin through an IGF1-dependent survival pathway in non-small cell lung cancer (NSCLC) cells: amphiregulin activates the IGF1 receptor that in turn induces the secretion of amphiregulin and IGF1. In the absence of serum, the NSCLC cell line H358 resists apoptosis and secretes factors protecting the NSCLC cell line H322 from serum deprivation apoptosis. IGF1 receptor inhibitor AG1024 as well as epidermal growth factor receptor inhibitors AG556 and ZD1839 restore apoptosis in H322 cells cultured in H358-conditioned medium. Accordingly, the anti-apoptotic activity of H358-conditioned medium is completely abolished after incubation with anti-amphiregulin neutralizing antibody and only partially with anti-IGF1 neutralizing antibody. H358-conditioned medium and amphiregulin induce IGF1 receptor phosphorylation in H322 cells, which is prevented by anti-amphiregulin neutralizing antibody but not by AG556 or ZD1839. H358 cells secrete a high level of amphiregulin that, in combination with IGF1, prevents serum deprivation apoptosis. Finally, IGF1 receptor inhibitor blocks amphiregulin and IGF1 release by H358 cells.

show abstract

Section: Ar and Igf1 Inhibit Serum Deprivation Apoptosis Of H358 And mentioning

confidence: 99%

Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines

Hurbin¹,

Dubrez²,

Coll

et al. 2002

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…Early evidence demonstrated increased TGFa expression in mammary tumors versus normal mammary gland Arteaga et al, 1988;Bates et al, 1988;Travers et al, 1988); however, the current paradigm for EGF family growth factor participation in breast cancer also involves the establishment of a pro-survival, proproliferative, autocrine stimulatory loop with EGFR. The EGFR has also been found to be overexpressed with or without gene ampli®cation in approximately 50% of breast cancers (Harris et al, 1988;Dahiya et al, 1998;Martinez-Lacaci et al, 1999, De Luca et al, 1999.…”

Section: Introductionmentioning

confidence: 99%

Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models

2000

View full text Add to dashboard Cite

“…Therefore, it is likely that no single growth factor will hold the masterkey to therapy. In this respect a mixture of AS oligonucleotides to Amphiregulin, Cripto and TGFoc was shown to inhibit the growth of a human breast carcinoma cell line in vitro, when individually applied at 0.7 jiM each (De Luca et al, 1999). The combination of different AS oligos significantly reduced xenograft tumor growth in nude mice treated in vivo, suggesting a possible therapeutic approach (De Luca et al, 2000).…”

Section: Over-expressed Growth Factorsmentioning

confidence: 96%

Cripto: A Target for Breast Cancer Treatment

Adamson¹

2004

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the lime for reviewing instructions, searching existing data sources gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204 Ariinqton VA 22202-4302 and to the Office nf Management and Budget, Paperwork Reduction Project (0704-01S8), Washington, DC 20503 '

show abstract

EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells

Cited by 43 publications

References 14 publications

Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines

Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines

Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models

Cripto: A Target for Breast Cancer Treatment

Contact Info

Product

Resources

About